SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥145.53+CN¥2.64 (+1.85%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.17% below the high.
Loading market information…
SHZ · 002349.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:57 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Jinghua Pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Jinghua Pharmaceutical Group Co., Ltd.’s forward annual dividend is CN¥0.09 per share, paid annual. The forward yield is 1.3% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jinghua Pharmaceutical Group Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1957 and headquartered in Nantong, China, Jinghua Pharmaceutical Group Co., Ltd. is a Chinese enterprise dedicated to the complete process of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, encompassing their research, development, manufacturing, and distribution. Its essential API offerings include a variety of compounds such as Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine. The company previously operated under the name Nantong Jinghua Pharmaceutical Co., Ltd.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥145.53+CN¥2.64 (+1.85%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.17% below the high.
CN¥40.58-CN¥0.72 (-1.74%)
Sichuan Kelun Pharmaceutical Co., Ltd. Class A’s quoted price sits in the upper half of its reported 52-week range, 23.11% below the high.
$6.86-$0.41 (-5.64%)
Regencell Bioscience Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 90.06% below the high.
CN¥21.59+CN¥0.39 (+1.84%)
Jiangsu Nhwa Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 15.99% below the high.
CN¥23.67+CN¥0.04 (+0.17%)
Guangdong Zhongsheng Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.93% below the high.
CN¥8.93+CN¥0.07 (+0.79%)
Zhejiang Xianju Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 11.14% below the high.
CN¥3.09+CN¥0.18 (+6.19%)
Guizhou Xinbang Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.54% below the high.
$4.04-$0.19 (-4.49%)
Aquestive Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.7% below the high.
